Peter Thule's research interests lie in the development of insulin gene therapy as a treatment for diabetes mellitus and investigations into hepatocellular effects of ectopic insulin production. His group's animal model utilizes a metabolically regulated, hepatic specific gene promoter to drive expression of an insulin transgene in the livers of diabetic rats. Administration of viral vectors containing these promoters coupled to a human insulin cDNA, normalizes blood sugars in diabetic rodents.